Prostate Cancer

Prostate Enlarging on Dutasteride, PSA Rising with Gleason 6 | Mark Scholz, MD, PCRI [Video]

Prostate Enlarging on Dutasteride, PSA Rising with Gleason 6 | Mark Scholz, MD, PCRI

Mark Scholz, MD, a medical oncologist specializing exclusively in prostate cancer, answers patients’ questions from our YouTube comments on treating an enlarging prostate after dutasteride has failed to have an effect, active surveillance in a man with a rising PSA, and intermittent hormone therapy in men with advanced prostate cancer.

0:05 I have an enlarged prostate and Gleason 6 prostate cancer. I’ve been on dutasteride for about six months, but it has failed to slow my prostate growth. What should I do?

2:17 I am 69 years old. My PSA started at 1.2, but has since risen to 11 over ten years. An MRI and biopsy show Gleason 6. My prostate size is about that of a 40-year old man and my Prolaris test says the cancer is non-aggressive. Considering my rise in PSA, is there anything else that I should do?

5:07 In this man’s case (from the previous questions) how often would you recommend that he get his PSA checked and/or imaging studies performed?

5:28 What is the latest research on taking holidays from ADT? When do you recommend restarting ADT after a holiday from treatment?

Don’t know your stage? Take the quiz: Visit

To learn more about prostate cancer visit

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 641-7274 with any questions that you have. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute’s YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #Prostate #MarkScholzMD

Watch/Read More
Prostate Cancer

PSMA Imaging: VISION Trial with Dr. Scott Tagawa [Video]

In this video, moderator Dr. Agarwal discusses the VISION trial with Dr. Scott Tagawa, a co-author on the New England Journal Medicine Paper on the primary results of the VISION Trial. They continue their discussion covering how lutetium-177 PSMA-617 will be incorporated into treating patients with metastatic CRPC. To end their conversation, Dr. Tagawa talks about how this agent and similar agents or approaches will be moving to other earlier states of prostate cancer.The Moderator: Neeraj Agarwal, MD, is an internationally recognized physician-scientist in the field of genitourinary cancers and is a Professor of medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI.The Panel of Experts: Dr. Jeremie Calais: Director of the UCLA Clinical theranostic Program and an Associate Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. Dr. Calais received his MD degree from the University of Paris, France. He is a nuclear medicine physician specializing in cancer imaging and theranostics.Scott T. Tagawa, MD, MS, FACP: Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer.Jonathan Tward, MD, Ph.D.: A tenured Professor in the Department of Radiation Oncology at the University of Utah who holds the Rudolph P. and Edna S. Reese Endowed Research Professorship. He is recognized as a major authority and key-opinion leader in treating prostate, bladder, and penile cancers. Dr. Tward is the leader of the Huntsman Cancer Institute's (HCI) Genitourinary Cancers Center (GUCC).